505582598 07/22/2019 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5629397

SUBMISSION TYPE: NATURE OF CONVEYANCE:		NEW ASSIGNMENT	NEW ASSIGNMENT		
		NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY			
CONVEYING PARTY D	ΑΤΑ				
Name				Execution Date	
SPECGX LLC				07/19/2019	
RECEIVING PARTY DA	TA				
Name:	DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT				
Street Address:	60 WALL	60 WALL STREET			
City:	NEW YOF	NEW YORK			
State/Country:	NEW YOF	}K			
Postal Code:	10005				
Application Number:	15	714137			
PROPERTY NUMBERS Property Type		Number			
		/1415/			
Application Number	15	568587			
Application Number:		568587			
Application Number:	16	002199			
Application Number: Application Number:	16				
Application Number:	16) 16) 15!	002199 002190			
Application Number: Application Number: Application Number:	160 160 159 159	002199 002190 977415			
Application Number: Application Number: Application Number: Application Number:	160 160 159 159 159	002199 002190 977415 464865			
Application Number: Application Number: Application Number: Application Number: Application Number:	160 160 159 159 160 160	002199 002190 977415 464865 002285			
Application Number: Application Number: Application Number: Application Number: Application Number: Application Number:	160 160 159 159 160 160 160	002199 002190 977415 464865 002285 201645			
Application Number:Application Number:Application Number:Application Number:Application Number:Application Number:Application Number:Application Number:	160 160 159 159 160 160 160 160 62	002199 002190 977415 464865 002285 201645 219253			

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

0

Address Line 4: LOS ANGELES, CALIFORNIA 90071					
ATTORNEY DOCKET NUMBER:	1111779-2659-S216				
NAME OF SUBMITTER:	JUSTINE LU				
SIGNATURE:	/Justine Lu/				
DATE SIGNED:	07/22/2019				
Total Attachments: 6 source=MNK - IP Supplement - Patents - SpecGX LLC (Executed)#page1.tif source=MNK - IP Supplement - Patents - SpecGX LLC (Executed)#page2.tif source=MNK - IP Supplement - Patents - SpecGX LLC (Executed)#page3.tif source=MNK - IP Supplement - Patents - SpecGX LLC (Executed)#page4.tif source=MNK - IP Supplement - Patents - SpecGX LLC (Executed)#page5.tif source=MNK - IP Supplement - Patents - SpecGX LLC (Executed)#page6.tif					

Notice of Grant of Security Interest in Intellectual Property

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS, dated as of July 19, 2019 (this "*Agreement*"), made by SpecGX LLC, a Delaware limited liability company (the "*Pledg-or*"), in favor of DEUTSCHE BANK AG NEW YORK BRANCH, as Collateral Agent (as defined below).

Reference is made to the U.S. Collateral Agreement dated as of March 19, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the "U.S. Collateral Agreement"), among Mallinckrodt International Finance S.A., a public limited liability company (société anonyme) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 124, boulevard de la Pétrusse, L-2330 Luxembourg, and registered with the Luxembourg Trade and Companies Register (R.C.S. Luxembourg) under number B 172.865 (the "Lux Borrower"), MALLINCKRODT CB LLC (the "Co-Borrower", and together with the Lux Borrower, the "Borrowers"), Mallinckrodt Holdings GmbH (as successor by merger to Mallinckrodt Finance GmbH) (the "Swiss Finco"), each other Subsidiary Loan Party listed on the signature pages hereof and each other Subsidiary Loan Party that becomes a party hereto after the date hereof and DEUTSCHE BANK AG NEW YORK BRANCH, as collateral agent (together with its successors and assigns in such capacity, the "Collateral Agent") for the Secured Parties (as defined therein). The parties hereto agree as follows:

SECTION 1. *Terms*. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the U.S. Collateral Agreement. The rules of construction specified in Section 1.01(b) of the U.S. Collateral Agreement also apply to this Agreement.

SECTION 2. *Grant of Security Interest*. As security for the payment and performance, as applicable, in full of its Secured Obligations, the Pledgor pursuant to the U.S. Collateral Agreement did, and hereby does, assign and pledge to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor's right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the "<u>IP Collateral</u>"):

all Patents of the United States of America, including those listed on Schedule I;

SECTION 3. U.S. Collateral Agreement. The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the U.S. Collateral Agreement. The Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the U.S. Collateral Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the U.S. Collateral Agreement, the terms of the U.S. Collateral Agreement shall govern.

PATENT REEL: 049823 FRAME: 0235 SECTION 4. *Counterparts*. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed original.

SECTION 5. Governing Law. THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

SPECGX LLC

By:

Name: John Einwalter Title: Vice President & Treasurer

[Signature Page to Notice of Grant of Security Interest in Patents]
PATENT

REEL: 049823 FRAME: 0237

DEUTSCHE BANK AG NEW YORK BRANCH, as Collateral Agent,

By: Name: Yumi Okabe Title Vice President

Bý Alicia Schug Vice President Name: Title:

[Signature Page to Notice of Grant of Security Interest in Patents]

PATENT REEL: 049823 FRAME: 0238

Schedule I to Notice of Grant of Security Interest in Patents

U.S. Patent Registrations

N/A

U.S. Patent Applications

	Application		
Patent	Application No.	Date	Owner
Tamper-Resistant Immediate	15/714137	September 25, 2017	SpecGX LLC
Release Formulations			
TR Pan Coater Apparatus and	15/568587	October 23, 2017	SpecGX LLC
Method			
ABUSE DETERRENT	16/002199	June 7, 2018	SpecGX LLC
IMMEDIATE RELEASE			
FORMULATIONS CON-			
TAINING GLUCOMANNAN			
TAMPER-RESISTANT	16/002190	June 7, 2018	SpecGX LLC
IMMEDIATE RELEASE			
FORMULATIONS			
TAMPER-RESISTANT	15/977415	May 11, 2018	SpecGX LLC
IMMEDIATE RELEASE			
FORMULATIONS			
TAMPER RESISTANT	15/464865	March 21, 2017	SpecGX LLC
FORMULATIONS FOR ORAL			
SOLID EXTENDED			
RELEASE DOSAGE FORMS			
DELAYED SUSTAINED	16/002285	June 7, 2018	SpecGX LLC
RELEASE			
PHARMACEUTICAL			
PREPARATION			
A SIMPLIFIED PROCEDURE	16/201645	November 27, 2018	SpecGX LLC
FOR THE INDUSTRIAL			
SCALE MANUFACTURE OF			
LISDEXAMPHETAMINE			
DIMESYLATE (1) USING A			
"ONE-POT"™ PROCEDURE			
FROM AMPHETAMINE			
SALTS			
ONE STEP MILLING	16/219253	December 13, 2018	SpecGX LLC
PROCESS FOR PREPARING			
MICRONIZED			
PALIPERIDONE ESTERS			

TAMPER-RESISTANT IMMEDIATE RELEASE CAPSULE DOSAGE FORM CONTAINING ORGANIC ACID	62/736020	September 25, 2018	SpecGX LLC
A CONVENIENT AND EFFECTIVE WAY TO CONVERT (MINOR AMOUNT OF) AL- PHA,BETA-UNSATURATED KETONE TO SATURATED KETONE IN THE FINISHING DRUG SUBSTANCE	15/710990	September 21, 2017	SpecGX LLC
PROCESSES FOR THE LARGE SCALE MANU- FACTURE OF SUFENTANIL CITRATE AND SUFENTANIL BASE	16/254074	January 22, 2019	SpecGX LLC